The Future of Diffuse Large B-Cell Lymphoma (DLBCL) Treatment: Insights from Global Research
Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, shares new insights into the global clinical trial landscape for Diffuse Large B-Cell Lymphoma (DLBCL), further reinforcing its leadership in oncology research.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241115682139/en/
DLBCL is the most prevalent and aggressive subtype of non-Hodgkin lymphoma (NHL), accounting for 30-40% of cases worldwide. Its heterogeneity, characterized by key subtypes like Germinal Center B-cell (GCB) and Activated B-cell (ABC), poses significant challenges in treatment. Novotech’s latest analysis highlights these complexities while highlighting ongoing advancements in therapeutic strategies to address this aggressive disease.
Key Insights from DLBCL Clinical Trials
Since 2019, more than 1,500 clinical trials for DLBCL have been initiated globally, indicating strong research momentum:
- Asia-Pacific: Leads with 41% of trials, driven largely by China’s clinical research activity.
- North America: Accounts for 33% of trials, with the United States leading in trial volume.
- Europe: Represents 19% of trials, focusing on both hematological and solid tumor research.
These findings highlight the global effort to improve treatment options for DLBCL patients.
Advances in DLBCL Treatment
Novotech’s report also highlights breakthroughs in DLBCL treatment, moving beyond traditional chemotherapy to explore new therapeutic options:
- Targeted therapies: Phase III trials for Mosunetuzumab and Selinexor are showing promise, particularly for relapsed or refractory DLBCL patients.
- Immunotherapies: Novotech is involved in the development of CAR T-cell therapies, checkpoint inhibitors, and bispecific antibodies, which have shown strong efficacy in high-risk DLBCL patients who do not respond to standard treatments like R-CHOP.
Ongoing efforts to personalize DLBCL treatment through genomic profiling and molecular diagnostics are expected to yield more precise and effective treatment strategies. In combination with innovative therapies such as EZH2 inhibitors targeting GCB subtypes and novel agents addressing the ABC subtype, these approaches are advancing more tailored and successful interventions.
Download the Full Report
For detailed analysis of the DLBCL clinical trial landscape, including emerging treatment strategies and global trial trends, download Novotech’s latest DLBCL Global Clinical Trial Landscape Report.
About Novotech Novotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Frost &Sullivan 2024 Global Biotech CRO of the year award, Clinical Trials Arena Excellence Awards 2024, 2024 Employer of Choice, 2024 Great Place to Work in the US, 2024 Brandon Hall Gold Award, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241115682139/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting samarbejder med MJB Technology Solutions om at fremme digitale transformationsmuligheder7.9.2025 08:24:00 CEST | Pressemeddelelse
Andersen Consulting styrker sin platform for digital transformation gennem et samarbejde med det canadiske firma MJB Technology Solutions, der er specialiseret i ServiceNow, kunstig intelligens, analyse og IT-transformation. MJB Technology Solutions blev stiftet i 2002 og udvikler skræddersyet software, digitale platforme og operationelle systemer til kunder inden for sektorer som banker, telekommunikation og produktion. Virksomhedens kernekompetencer omfatter komplekse ServiceNow-tjenester samt AI-baserede løsninger, business intelligence og analyse samt digital IT-strategi – og de leverer konsekvent målbare resultater og langsigtet værdi. "Gennem to årtier har vi leveret specialudviklede løsninger, der hjælper vores kunder med at tackle forretningskritiske udfordringer," siger Mark Bains, administrerende direktør hos MJB Technology Solutions. "Vores samarbejde med Andersen Consulting markerer et nyt kapitel i, hvordan vi skalerer innovation globalt, samtidig med at vi forbliver tro m
U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease6.9.2025 02:45:00 CEST | Press release
− Approval Expands Use of VONVENDI to Include Routine Prophylaxis to Reduce the Frequency of Bleeding Episodes in Adults with Type 1 and 2 Von Willebrand Disease (VWD) and On-Demand and Perioperative Management of Bleeding in Pediatric Patients with VWD1 − VONVENDI is the Only Recombinant Von Willebrand Factor Replacement Therapy with Approved Indications in Adults and Children with VWD1 − VWD, the Most Common Bleeding Disorder, Impacts More Than 3 Million People in the U.S.2 Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for VONVENDI® [von Willebrand factor (Recombinant)], expanding the indication to include routine prophylaxis to reduce the frequency of bleeding episodes in adults with von Willebrand Disease (VWD), including those with Type 1 and 2 disease, and on-demand and perioperative management of bleeding in pediatric patients with VWD. VONVENDI was previously approve
Samsung Unveils “AI Home: Future Living, Now” Vision at IFA 20255.9.2025 23:34:00 CEST | Press release
From well-being to energy efficiency, Bespoke AI, Vision AI, and Galaxy AI transform the way we live and connect. At Innovation For All (IFA) 2025, Samsung Electronics showcased its vision for “AI Home: Future Living, Now”. Samsung’s AI Home aims to be a reality people can experience today — not just in the future — and one designed for everyone, not just a select few. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250905654772/en/ Cheolgi Kim, Head of Digital Appliances, presents Future Living Now at Samsung’s IFA 2025 press conference in Berlin “At Samsung, we’re not just imagining the future of AI; we’re building it into everyday life. Samsung’s AI Home moves beyond smart devices to homes that truly understand you, adapt to your needs, and care for what matters most,” said Cheolgi Kim (CK), Executive Vice President and Head of Digital Appliances (DA) Business. “This is the beginning of a new era - where technology support
Andersen Consulting styrker end-to-end-teknologikompetencer via samarbejde med FirstQA Systems5.9.2025 19:44:00 CEST | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation og kunstig intelligens via en samarbejdsaftale med FirstQA Systems, der er en førende teknologileverandør, som er kendt for sin ekspertise inden for AI til virksomheder, digital transformation og cybersikkerhed. FirstQA Systems K.K. med hovedsæde i Japan siden 2011 er en konsulentdrevet teknologivirksomhed, der betjener Fortune 500-virksomheder og multinationale koncerner i Asien, Europa og Nordamerika. Virksomheden specialiserer sig i kunstig intelligens, digital transformation (med fokus på platformene ServiceNow, SAP og Salesforce) samt it- og OT-cybersikkerhed. Gennem sit datterselskab, Himitsu Lab Limited, leverer FirstQA Systems banebrydende Agentic AI-løsninger drevet af HIMITSU8™ Unified Development Framework (UDF)™. Virksomhedens brancheekspertise dækker bl.a. produktion, medicinalindustrien samt løsninger til bank- og finansverdenen. "Vores samarbejde med Andersen Consulting markerer et spændende sk
NetApp named a Leader by Gartner® in the 2025 Magic Quadrant™ for Enterprise Storage Platforms5.9.2025 17:15:00 CEST | Press release
Recognition reflects NetApp’s Ability to Execute and Completeness of Vision NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced it has been recognized by Gartner as a Leader in the 2025 Gartner Magic Quadrant for Enterprise Storage Platforms. NetApp believes this recognition reflects how the company’s continuous innovation helps customers build Intelligent Data Infrastructure to face modern technology challenges, including protection from cyber threats and using AI to drive data-based decisions. The evaluation was based on specific criteria that analyzed the company’s overall Completeness of Vision and Ability to Execute. According to Gartner, “Enterprise storage platforms offer platform-native service capabilities and product features for both structured and unstructured data workloads. Heads of infrastructure and operations should use this research to assess vendors in deploying a modern IT infrastructure platform for block, file and object storage.”
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom